EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD

Slideshow

A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?

   

Related Videos
Matthew Nudy, MD | Credit: Penn State Health
Kelley Branch, MD, MSc | Credit: University of Washington Medicine
Kelley Branch, MD, MS | Credit: University of Washington Medicine
David Berg, MD, MPH | Credit: Brigham and Women's
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Related Content
Stock imagery of diabetes related items. | Credit: Fotolia

ACP's New Type 2 Diabetes Guidance Recommends SGLT2is, GLP-1 RAs as Second-Line to Metformin

April 19th 2024
Article
2024 State of the Air: Record Highs in US Particle Pollution, with Dr. John Balmes

2024 State of the Air: Record Highs in US Particle Pollution, with John Balmes, MD

April 24th 2024
Podcast
Ersilia DeFilippis, MD | Credit: Columbia University

Ersilia DeFilippis, MD: Need for Equity, Policy Change in Heart Failure Transplant

April 16th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

April 17th 2024
Podcast
Safia Chatur, MD | Credit: X.com

Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes

April 12th 2024
Article
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University

Understanding Trends in Hypertrophic Cardiomyopathy-Related ED Visits, with Ahmad Masri, MD, MS

April 12th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.